Kevin Kunzmann

Why any physician needs to have a strong sense of a patients' clinical history to distinguish endometriosis symptoms.

The burdensome disorder is highly prevalent in women. What treatment options are currently available?

A new study found that physician mothers commonly have responsibilities outside of their children and patients—and that such burdens are linked to more anxiety and burnout.

The Mylan product has been approved as 3 different dosing strengths, inidicated for both asthma and COPD care.

A new cohort analysis shows patients switching or adding on the antipsychotic drug are not at a worse risk of suicide or other adverse events.

In the past 5 years, the administration has continually improved on the previous year's rate. More of the same should be anticipated in 2019.

Patients hospitalized for exacerbations due to asthma have a 29% longer stay if treated early with antibiotics.

The painful condition requires more options for women to recover without further discomfort.

A new study found the biggest burden of benzodiazepine-related visits have come from primary care physicians, and that efforts to limit sedative prescription may have to start there.

Obese/overweight patients aged 12 to 25 years old with uncontrolled asthma reported no significant improvements in asthma control compared to patients treated with soy oil control.

A new test for Mycoplasma genitalium showed near-perfect rates of detection in non-infected patient samples.

The FDA will decide this year whether the once-daily Merck therapies can be marketed as a switch-on drug for patients with suppressed HIV-1.

Investigators are now interested in assessing potential benefits of direct-acting antivirals for HCV patients who previously had liver cancer.

An Investigational New Drug application was approved to clinically assess AMT-130 as the first potential drug marketed for the neurodegenerative disease.

Why certain age-related factors particularly impact the mental health of women at the age their menopause symptoms appear.

The investigative SGLT1/2 dual inhibitor is scheduled to be considered for marketing approval by mid-March.

University of Washington investigators found great disparities in AEMT-driven death rates among states and age groups.

A four-year trial assessing the investigative vaccine in about 3000 pregnant women will announce efficacy results later this quarter.

The FDA has responded to the Janssen Pharmaceutical company's sNDA with a request for more data.

The antipsyhoctic could receive a new indication in 2019, and though the field of bipolar disorder care is far from perfect, it should improve with this addition.

The repeated dose vaccine from Sanofi Pasteur was assessed in 1300-plus patients aged 18 to 64. Currently, about 75% of US adults have not received a Tdap vaccination.

The imaging platform is now the only of its kind approved for optimizing blood clot removal in the US.

Why it's critical for physicians to remember that patients may not be as well-versed on the particularities of conceiving a child.

Flibanserin, a once-daily oral drug, is the only marketed therapy for female sexual dysfunction. Are more options needed?

A new study finds that age, gender, physician gender, income, and social behavior influence whether teenagers and young adults are confidential with their care providers.

The Second Chance app from University of Washington investigators is seeking FDA consideration in the near future.

The ProAir Digihaler, from Teva, will reach the US markets widescale in 2020 after receiving FDA approval.

There is currently just 1 FDA-approved therapy for women suffering from dysfunction. What's driving the disparity?

Why obstetricians and gynecologists need to consider the stigmas and telling signs of sexual dysfunction in female patients.

A new survey study found that less than half of food allergies reported by adults have actually been diagnosed by a physician.